89 related articles for article (PubMed ID: 2314099)
1. Muramyl dipeptide improves mononuclear phagocyte system function in obstructive jaundice.
Dunn CW; Horton JW
J Surg Res; 1990 Mar; 48(3):249-53. PubMed ID: 2314099
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of bacterial translocation in obstructive jaundice by muramyl tripeptide phosphatidylethanolamine in the rat.
Ding JW; Andersson R; Soltesz VL; Pärsson H; Johansson K; Wang W; Bengmark S
J Hepatol; 1994 Jun; 20(6):720-8. PubMed ID: 7930471
[TBL] [Abstract][Full Text] [Related]
3. Modification of reticuloendothelial function by muramyl dipeptide-encapsulated liposomes in jaundiced rats treated with biliary decompression.
Ding JW; Andersson R; Hultberg B; Soltesz V; Bengmark S
Scand J Gastroenterol; 1993 Jan; 28(1):53-62. PubMed ID: 8430273
[TBL] [Abstract][Full Text] [Related]
4. Improvement of normothermic rat liver ischemia/reperfusion by muramyl dipeptide.
Cursio R; Gugenheim J; Panaia-Ferrari P; Lasfar A; Tovey M; Chastanet S; Saint-Paul MC; Ferré C; Mouiel J
J Surg Res; 1998 Dec; 80(2):339-44. PubMed ID: 9878335
[TBL] [Abstract][Full Text] [Related]
5. Impaired bacterial clearance and trapping in obstructive jaundice.
Katz S; Grosfeld JL; Gross K; Plager DA; Ross D; Rosenthal RS; Hull M; Weber TR
Ann Surg; 1984 Jan; 199(1):14-20. PubMed ID: 6362581
[TBL] [Abstract][Full Text] [Related]
6. Contribution of portal systemic shunt to Kupffer cell dysfunction in obstructive jaundice.
Dunn CW; Horton JW; Megison SM; Vuitch MF
J Surg Res; 1991 Mar; 50(3):234-9. PubMed ID: 1999912
[TBL] [Abstract][Full Text] [Related]
7. Comparative effect of muramyl dipeptide in vivo and in vitro on the tumoricidal activity of rat peritoneal macrophages.
Reisser D; Jeannin JF; Lagadec P; Martin F
J Biol Response Mod; 1985 Oct; 4(5):460-3. PubMed ID: 4078593
[TBL] [Abstract][Full Text] [Related]
8. [Antitumoral activation of rat peritoneal macrophages by muramyl dipeptide in vitro].
Reisser D; Jeannin JF; Martin F
C R Seances Acad Sci III; 1982 Nov; 295(8):485-8. PubMed ID: 6819063
[TBL] [Abstract][Full Text] [Related]
9. Activation of rainbow trout (Oncorhynchus mykiss) phagocytes by muramyl dipeptide.
Kodama H; Hirota Y; Mukamoto M; Baba T; Azuma I
Dev Comp Immunol; 1993; 17(2):129-40. PubMed ID: 8388812
[TBL] [Abstract][Full Text] [Related]
10. Reticuloendothelial system phagocytic function in obstructive jaundice and its modification by a muramyl dipeptide analogue.
Pain JA; Collier DS; Ritson A
Eur Surg Res; 1987; 19(1):16-22. PubMed ID: 3792414
[TBL] [Abstract][Full Text] [Related]
11. Impaired hepatic bacterial clearance is reversed by surgical relief of obstructive jaundice.
Katz S; Yang R; Rodefeld MJ; Folkening WJ; Grosfeld JL
J Pediatr Surg; 1991 Apr; 26(4):401-5; discussion 405-6. PubMed ID: 2056399
[TBL] [Abstract][Full Text] [Related]
12. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.
Phillips NC; Moras ML; Chedid L; Lefrancier P; Bernard JM
Cancer Res; 1985 Jan; 45(1):128-34. PubMed ID: 3838084
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of tumoricidal activity and susceptibility to reactivation of subpopulations of rat liver macrophages.
Daemen T; Veninga A; Regts J; Scherphof GL
J Immunother (1991); 1991 Jun; 10(3):200-6. PubMed ID: 1868044
[TBL] [Abstract][Full Text] [Related]
14. Muramyl dipeptide does not induce slow-wave sleep or fever in rats.
Fornal C; Markus R; Radulovacki M
Peptides; 1984; 5(1):91-5. PubMed ID: 6709515
[TBL] [Abstract][Full Text] [Related]
15. Impaired clearance and organ localization of Candida albicans in obstructive jaundice.
Katz S; Merkel GJ; Folkening WJ; Rosenthal RS; Grosfeld JL
J Pediatr Surg; 1991 Aug; 26(8):904-6; discussion 907. PubMed ID: 1919981
[TBL] [Abstract][Full Text] [Related]
16. Modulation of natural killer cytotoxicity by muramyl dipeptide and trehalose dimycolate incorporated in squalane droplets.
Masihi KN; Lange W; Rohde-Schulz B
Cancer Immunol Immunother; 1987; 24(1):19-24. PubMed ID: 3815418
[TBL] [Abstract][Full Text] [Related]
17. Hepatic mixed-function oxidase system and microsomal lipid peroxidation in rats treated with a synthetic immunomodulator, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP).
Yanev S; Zídek Z; Kadiiska M; Serbinova E; Masek K; Stoytchev T
Methods Find Exp Clin Pharmacol; 1984 Jun; 6(6):311-5. PubMed ID: 6748821
[TBL] [Abstract][Full Text] [Related]
18. B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1992; 10(11):792-7. PubMed ID: 1441733
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages.
Saiki I; Fidler IJ
J Immunol; 1985 Jul; 135(1):684-8. PubMed ID: 3923117
[TBL] [Abstract][Full Text] [Related]
20. Effects of muramyl dipeptide and lead acetate on carbon clearance and endotoxin-induced mortality in mice.
Cheadle WG; Ausobsky JR; Trachtenberg LS; Lamont P; Polk HC
Am Surg; 1986 Nov; 52(11):613-7. PubMed ID: 3535600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
